AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.
Published April 7, 2022 By Vanessa Doctor, RN BioSpace Shares in Acadia Pharmaceuticals rose 5.71% to $27.22 per share at the close of NASDAQ Wednesday on positive late-stage data from the study […]
Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).
New York-based Anavex Life Sciences announced positive topline results from the company’s Phase III AVATAR trial of Anavex 2-73 (blarcamesione) in adult female patients with Rett syndrome.
Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.
Biohaven Pharmaceutical Holding Co. Ltd. said on Sept. 27 the company’s drug candidate, verdiperstat, failed to show effectiveness in treating a rare neurological disorder called multiple system atrophy (MSA).
More than 55 million people worldwide are living with dementia, a neurological disorder that robs them of their memory and costs the world $1.3 trillion a year, the World Health Organization (WHO) said on Sept. 2.
The U.S. Food and Drug Administration is planning a new warning for Johnson & Johnson’s Covid-19 vaccine over a rare but serious side effect, Guillain-Barré syndrome (GBS).
Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Biogen will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders.
